EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study

Eva M M Verkolf iD, Jacob L van Dam iD, Esther N Dekker iD, Quisette P Janssen iD, Laura R Prakash iD, Anissa DeSilva, Roeland F de Wilde, Marc G Besselink iD, Alice C Wei iD, Amer H Zureikat iD, Matthew H G Katz, Ching-Wei D Tzeng iD und 2 weitere

JNCI: Journal of the National Cancer Institute · 2026

DOI: 10.1093/jnci/djag033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Eva M M Verkolf und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Pancreatectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant chemotherapy is increasingly used for patients with localized pancreatic ductal adenocarcinoma (PDAC), although the likelihood of subsequent resection remains uncertain. The aim of this study was to develop a prediction model using baseline characteristics to estimate the probability of meeting prespecified criteria for resection after induction FOLFIRINOX.

Methods

This retrospective study included patients with localized PDAC who received (m)FOLFIRINOX as initial treatment in 5 referral centers in the United States and the Netherlands (2012-2019). Multivariable logistic regression identified independent predictors of resection and was used to develop a prediction model.

Results

Among 1835 patients, 18.9% were classified as potentially resectable (PR), 28.9% as borderline resectable (BR), and 52.2% as locally advanced (LA). Observed resection rates were 70.5% for PR, 53.1% for BR, and 17.8% for LA PDAC. Unfavorable independent factors for resection were advanced anatomical stage (BR, OR = 0.51; 95% CI = 0.37 to 0.69 and LA, OR = 0.11; 95% CI = 0.08 to 0.15), baseline CA19-9 >500 U/mL (OR = 0.60; 95% CI = 0.46 to 0.77), a WHO performance status of ≥1 (OR = 0.41; 95% CI = 0.33 to 0.52), and tumor size on baseline imaging >40 mm (OR = 0.62; 95% CI = 0.48 to 0.80). Depending on these factors, the predicted probability of resection ranged from 6.7% to 81.7%.

Conclusion

At diagnosis, the probability of resection after induction (m)FOLFIRINOX for localized PDAC ranged from 7% to 82%, depending on anatomical stage, CA19-9 level, performance status, and tumor size at baseline. This prediction model may help communicate realistic expectations for the probability of resection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatectomyAdenocarcinomaHumansFemaleOxaliplatinLeucovorinAgedIrinotecanRetrospective StudiesMaleFluorouracilNeoadjuvant TherapyMiddle AgedNetherlandsUnited States

Substanzen

folfirinoxOxaliplatinLeucovorinIrinotecanFluorouracil

Autor:innen und Institutionen

  • Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
  • Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Surgical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

ORCID-Profile: Eva M M Verkolf, Jacob L van Dam, Esther N Dekker, Quisette P Janssen, Laura R Prakash, Marc G Besselink, Alice C Wei, Amer H Zureikat, Ching-Wei D Tzeng, Bas Groot Koerkamp

Förderung

  • NCI NIH HHS
  • Dutch Cancer Society

Zitieren

APA

Verkolf, E. M. M., van Dam, J. L., Dekker, E. N., Janssen, Q. P., Prakash, L. R., DeSilva, A., de Wilde, R. F., Besselink, M. G., Wei, A. C., Zureikat, A. H., Katz, M. H. G., Tzeng, C. D., Groot Koerkamp, B., & Trans-Atlantic Pancreatic Surgery (TAPS) Consortium (2026). Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag033

Vancouver

Verkolf EMM, van Dam JL, Dekker EN, Janssen QP, Prakash LR, DeSilva A, et al. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djag033

BibTeX
@article{Verkolf2026,
  author = {Verkolf, Eva M M and van Dam, Jacob L and Dekker, Esther N and Janssen, Quisette P and Prakash, Laura R and DeSilva, Anissa and de Wilde, Roeland F and Besselink, Marc G and Wei, Alice C and Zureikat, Amer H and Katz, Matthew H G and Tzeng, Ching-Wei D and Groot Koerkamp, Bas and Trans-Atlantic Pancreatic Surgery (TAPS) Consortium, Trans-Atlantic Pancreatic Surgery (TAPS) Consortium},
  title = {Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  doi = {10.1093/jnci/djag033}
}
Kostenlos starten →